Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
| 5.19 | |
| 4.98 | |
| - | |
| 5.2296 | |
| 4.86 | |
| 1.8001-152.4 | |
| 15 799 K | |
| 3 044 K | |
| 0 | |
| -5.47 | |
| -0.934 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Investing.com -- U.S. futures traded largely unchanged Thursday, with investors largely shutting up shop as a positive year on Wall Street draws near to a close. Here are some of the biggest premarke...
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWS...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
